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Abstract
Background: To present a coincidence of macular telangiectasia type 2 and solitary retinal astrocytic hamartoma in
one patient.
Case presentation: A 50-year-old woman was examined in the Department of Ophthalmology of University
hospital Kralovske Vinohrady for complaints of metamorphopsia in her left eye. Her uncorrected visual acuity
(VA) was 4/4 on Early Treatment Diabetic Retinopathy Study charts (ETDRS), on the retina of her left eye
white, prominent, partially calcified tumour 1 disc diameter in diameter, 1,5 disc diameter from the foveola
was detected on the retina. In the macular region of both eyes, parafoveal greying with crystalline deposits
and changes in retinal vasculature were visible. We performed following examinations: fluorescein angiography (FA),
B-scan ultrasound, spectral domain optical coherence tomography (SD-OCT) including photo documentation.
FA showed partial hyperfluorescence of mulberry-like surface of the tumour typical for retinal astrocytic
hamartoma. Parafoveally in both eyes, leakage from parafoveal telangiectasia was apparent. SD-OCT showed
cystoid space in the macular region of both eyes as well as changes in inner and outer photoreceptor
segment junction in left eye. SD-OCT of the tumour showed proliferation in retinal nerve fibre layer with
normal structure of underlying retinal layers and choroid. Ultrasound examination of the tumour detected
solid, highly echogenic prominent tumour with high reflectivity and acoustic shadow.
Conclusion: A coincidence of two relatively rare clinical units, macular telangiectasia type 2 and solitary
astrocytic hamartoma was detected as a unique and rare observation.
Keywords: Astrocytic hamartoma, Macular telangiectasia type 2, Fluorescein angiography (FA), Optical
coherence tomography (SD-OCT), Case report
Background
Retinal astrocytic hamartoma is a benign tumour formed
through proliferation of well differentiated astrocytes,
mulberry-like based on ophthalmoscopy. It is most
common in paediatric patients with tuberous sclerosis
or neurofibromatosis [1]. These tumours may be multiple
and bilateral in patients with tuberous sclerosis. Both
these diseases are classified as the so called phacomatoses,
i.e. autosomal dominant diseases with variable penetration
and expressivity. Organ symptomatology of phacomatoses
(derived from the Greek word "phacoma" or congenital
condition; established by Van der Hoeve, Dutch ophthal-
mologist in 1921) is variegated within the framework of
congenital dysplasia of germ layers. In these neuroectoder-
mal forms, it most commonly involves the skin, nervous
system and the eye. It is found rarely as unrelated to these
diseases, frequently representing an accidental finding in
the retina of adult patients [1]. Macular telangiectasia
type 2 is a progressive bilateral disease of the macula
of unknown etiology, associated with changes in the
macular capillary network and retinal atrophy [2]. It may
be complicated by the formation of a neovascular
membrane and macular hole.
* Correspondence: pencak@volny.cz
1Department of Ophthalmology, University Hospital Kralovske Vinohrady and
3rd Medical Faculty, Srobarova 1150/50, Prague 10 100 34, Czech Republic
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pencak et al. BMC Ophthalmology  (2016) 16:200 
DOI 10.1186/s12886-016-0377-z
Case presentation
In February 2014, a 50-year-old Caucasian female patient
was referred to our department due to suspected chorio-
retinitis in the left eye. The patient reported metamor-
phopsia in the left eye lasting about 6 months. Both
personal and ocular histories were free of any noteworthy
facts. VA was 4/4 (ETDRS) natural in both eyes; intraocu-
lar pressure was 26 mmHg in the right eye and 23 mmHg
in the left eye. The finding in the anterior segment of both
the right and left eyes was quite physiological when exam-
ined using the slit lamp. Biomicroscopic examination of
the fundus of the left eye revealed a clear, prominent
whitish tumour with calcification at the centre (Fig. 1a)
sized 1 disc diameter, up in the temporal region at the
edge of the macular area, 1.5 disc diameter from the
foveola. No supply vasculature or vascular drainage were
visible. Furthermore, parafoveal greying of the retina was
visible in the parafoveolar temporal regions in both eyes,
with small crystalline deposits and impaired capillary net-
work structure with small telangiectasias (Fig. 1a), better
visible in red-free photographic documentation (Fig. 1b).
Autofluorescence of the fundus in the left eye showed a
mild decrease in autofluorescence in the area of the
tumour with hyperautofluorescence at the calcification
site (Fig. 2). The macular regions of both eyes showed
a mild increase in autofluorescence. Fluorescein angio-
graphy showed mild fluorescein leakage at the tumour site
in the left eye in late phases, with accentuation of the
mulberry-like structure of the tumour. In the macular
regions of both eyes, the telangiectasias were coloured
in early phases with fluorescein leakage in the foveola
in late phases (Fig. 3). SD-OCT of the tumour showed
proliferation in the retinal nerve fibre layer with a normal
structure of deeper retinal and choroid layers (Fig. 4) with
centrally located calcification associated with an acoustic
shadow. In the area of the foveola with normal contours,
small cystoid areas were visible in both eyes, as well as
small areas of impaired retinal architecture at the junction
of external and internal photoreceptor segments (Fig. 5).
Ultrasound assessment of the left eye showed a solid,
highly echogenic lesion in the temporal region above the
central area, prominent by 0.65 mm, with high reflectivity
85-90 % with central calcification and an indicated acous-
tic shadow (Fig. 6). The finding was concluded as macular
telangiectasia type 2 associated with a solitary retinal
astrocytic hamartoma. No skin alterations were shown in
the patient, in the sense of neuroectodermal phacoma-
toses, and her general condition was not associated with
neurological symptomatology either. The additionally
collected history confirmed no family burden with the
above mentioned diseases. The 85-year-old mother of
the patient has been followed at our department due to
bilateral active neovascular membrane; however, the
advanced stage of the finding at the time of diagnosis
prevented us from determining whether it had developed
in connection with macular telangiectasia of the mother.
To confirm our diagnosis and to rule out familial form
of macular telangiectasia type 2 we also examined the
47-year-old brother and, with consent of his parents,
7-year-old son of the patient but found no signs of
macular telangiectasia or astrocytic hamartoma.
Considering that currently no efficient therapy of macu-
lar telangiectasia type 2 is known, and given the stability
of the astrocytic hamartoma without any signs of growth
after 18 months of follow-up, the patient is only actively
followed without any therapy for now.
Discussion
In most cases, astrocytic hamartomas are benign lesions
showing no tendency to grow and cause complications
and without any need for a therapeutic intervention.
The ophthalmological presentation is very variable ran-
ging from flat to elevated lesions of whitish or yellow
colour. They tend to be slightly opaque or transparent,
with not very well defined boundaries. Calcifications are
common in the lesion. Spontaneous regression of the
tumour has also been observed [3, 4]. However, cases of
progressive growth can also be found in the literature,
associated with exudative retinal detachment, intravitreal
bleeding and dissemination, and with the development
of neovascular glaucoma [5–8]. These cases can be treated
with laser coagulation, cryotherapy or photodynamic
therapy at the tumour site [9, 10]. A surgery is necessary
in cases of retinal detachment. Severe neovascular glau-
coma may be an indication for bulbar enucleation [5]. It
is unclear whether solitary astrocytic hamartomas not
Fig. 1 Colour fundus photography (a). Whitish tumour with
calcification at the centre in the upper temporal region of the left
eye. Retinal greying with small crystalline deposits and impaired
structure of the capillary network with small telangiectasias in
temporal parafoveolar region of both eyes. All changes are better
visible in red-free documentation of the fundus (b)
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associated with general symptoms of phacomatoses
represent a separate clinical unit or whether they are
a partial expression of tuberous sclerosis or a forme
fruste [1]. Neurofibromatosis (or von Recklinghausen
disease) is associated with typical discoloured café au lait
skin patches and with plexiform neurofibromas in the area
of eyelids and central nervous system (CNS) meningiomas
[11–13]. Tuberous sclerosis (or Bourneville-Pringle
disease) is associated with the ocular finding of adenoma
sebaceum – butterfly-like vascularized red papulae on
the skin of the nose and face or, possibly, in rare cases
discoloured café au lait skin patches; astrocytic hamar-
toma may also develop in the CNS and cause epilepsy.
Fluorescein angiography clearly shows a network of
small capillaries of the tumour in the arterial and venous
phase, later accompanied by its homogeneous hyper-
fluorescence [1, 14], gaining a mulberry-like appearance
of the surface [14]. Tumour autofluorescence depends
on the range of calcification. The calcified part of the
tumour shows strong autofluorescence; noncalcified parts
block retinal autofluorescence [15]. Optical coherence
tomography shows a hyperreflexive formation growing
from the layer of retinal nerve fibres with a preserved
structure of external layers of the retina and smooth
transition to the surrounding normal retina. A shadow
may be apparent, caused by calcifications in the tumour.
The finding may also be associated with vitreous traction
on the tumour surface and an edema in the area of the
tumour or in the macula [16]. Ultrasound examination
shows astrocytic hamartoma as an elevation at the lesion
site with high reflectivity, often with calcifications. A
fine-needle biopsy can be performed in the case of unclear
findings [17].
As regards differential diagnosis, several additional
modalities should be considered. In particular, other glial
tumours of the retina are concerned – presumed solitary
circumscribed retinal astrocytic proliferation (PSCRAP)
and acquired retinal astrocytoma [1].
PSCRAP is found in elderly patients without a history
of tuberous sclerosis or neurofibromatosis. Compared
to astrocytic hamartoma, such lesions are usually well
circumscribed, unilateral flat formations, shadowing
deeper retinal structures. They do not include calcifica-
tions. SD-OCT scans clearly show their origin in the nerve
fibres layer with the shadowing of deeper retinal layers.
No edema is usually present at the lesion site or in the
macula. They are stable lesions without any tendency to
grow and cause complications [18].
Acquired retinal astrocytoma is found in adult patients
without a history of tuberous sclerosis or neurofibroma-
tosis [1]. It is a solitary yellowish tumour. Calcifications
are not usually present. Unlike astrocytic hamartoma,
the astrocytoma tends to grow slowly, which is usually
associated with intraretinal exudation and secondary
retinal detachment [5–8]. Our patient did not meet
the criteria for any of these diagnoses.
Fig. 2 Hypoautofluorescence at the lesion site with hyperautofluorescence of the central calcification in the left eye. Mild increase in
autofluorescence in macular regions of both eyes
Fig. 3 Late phase FA – leakage from parafoveolar telangiectasias in the macula, leakage in the tumour area in the left eye, with accentuation of
the mulberry-like structure of the tumour
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Macular telangiectasia type 2 is a progressive bilateral
disease of the macula of unknown etiology, with charac-
teristic alterations of the macular capillary network
and with the formation of parafoveolar telangiectasias;
in later stages it shows dilated capillaries and retinal
atrophy [2, 19]. Other characteristics include reduced
transparency of the retina (greying), crystalline deposits,
foveal atrophy and retinal pigment epithelium hyperplasia.
Müller cell counts of the retina [20] also decrease, as well
as the density of macular pigments lutein and zeaxanthin
[21]. All these alterations are usually most prominent in
the temporal region from the foveola, up to about 1 disc
diameter, but they may also involve a circular area around
the foveola. The alterations do not respect the horizontal
raphe of the retina. The disease may be complicated by
the development of neovascular membrane [2, 19] and
macular hole [2, 22]. Prevalence of the disease in the white
population has been reported between 0.004 % and 0.1 %
[23–25], with the same incidence in both sexes [2]. Family
incidence of the disease has been known [2, 26, 27].
Autosomal dominant inheritance is presumed with re-
duced penetration and variable expressivity. No specific
gene responsible for the disease has been identified [27].
Several classifications of the disease have been proposed.
Gass and Blodi proposed to divide the disease into 5
stages based on chronological development of alterations
in the fundus [2]. Yannuzi et al. suggested dividing the
disease to a nonproliferative and proliferative stage [19].
Many therapeutical approaches have been tried – laser
photocoagulation of the retina [2, 28], intravitreal triam-
cinolone [29, 30], photodynamic therapy [31, 32], and
antiVEGF intravitreal injections [33, 34], [32, 35]. Efficacy
of antiVEGF products and photodynamic therapy has
been shown in findings complicated by neovascular
membrane [36–40]. No efficient therapy has been known
yet for the nonproliferative stage of the disease [32, 41].
Concurrence of astrocytic hamartoma and telangiec-
tasias has been described [42]. However, this was related
to a unilateral finding in a patient with tuberous scle-
rosis. The astrocytic hamartoma was flat, diffuse, not
quite clearly expressed. Neovascularizations localized in
Fig. 4 OCT at the tumour site in the left eye – proliferation in
the retinal nerve fibre layer with normal structure of deeper
layers of the retina and normal choroidea; a shadow at the
calcification site
Fig. 5 OCT of the macula of the right (a) and left (b) eye – slight cystic infiltration in both eyes and areas of impairment of retinal architecture at
the junction of external and internal photoreceptor segments in the left eye
Fig. 6 Ultrasound of the left eye – solid, highly echogenic,
prominent lesion with high reflectivity and an indicated
acoustic shadow
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the superior region from the papilla and along the infe-
rotemporal arcade were already present at the time of
the diagnosis. Telangiectasias in the macular area, in the
inferior and nasal regions from the foveola, were disco-
vered in year 2 of the patient follow-up; hard exudates
were present in the area of the telangiectasias, and FA
clearly showed leakage from the telangiectasias. The
finding in the patient thus does not correspond to a
finding typical for macular telangiectasia type 2.
Conclusion
Concurrent incidence of solitary astrocytic hamartoma
of the retina and of macular telangiectasia type 2 was
present in our patient. We could not find any evidence
of any relationship between these two diseases in available
literature (PubMed). In this case, it is only an accidental
concurrence of two diseases given that unilateral retinal
astrocytic hamartoma is combined with a bilateral finding
of macular telangiectasia type 2.
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